| abstract |
The present invention relates to the medical field, particularly to the use of new formulations of adjuvants as vaccinal antigenes. The technical objective of the present invention is precisely the development of formulations capable of raising and/or modulating the immune response of the organism to vaccinal antigenes at serum and mucus levels. In order to attain such objective, a formulation has been developed which contains as fundamental components the surface antigene of the B hepatitis virus and the acemanane in adequate proportions. As an extension of such result, formulations have been developed wherein: a) HBsAg is used as carrier of homologous and heterologous antigenes; b) systems for transmitting particulate antigens and c) soluble antigens, in combination with the acemanane in specific proportions. The formulations of this invention are applicable to the pharmaceutical industry as vaccinal formulations both for human and veterinary use. |